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Abstract. 
 
Utrophin is a large cytoskeletal protein that 
is homologous to dystrophin, the protein mutated in 
Duchenne and Becker muscular dystrophy. In skeletal 
muscle, dystrophin is broadly distributed along the sar-
colemma whereas utrophin is concentrated at the neu-
romuscular junction. This differential localization, 
along with studies on cultured cells, led to the sugges-
tion that utrophin is required for synaptic differentia-
tion. In addition, utrophin is present in numerous non-
muscle cells, suggesting that it may have a more 
generalized role in the maintenance of cellular integ-
rity. To test these hypotheses we generated and charac-
terized utrophin-deficient mutant mice. These mutant 
mice were normal in appearance and behavior and 
showed no obvious defects in muscle or nonmuscle tis-
sue. Detailed analysis, however, revealed that the den-
sity of acetylcholine receptors and the number of junc-
tional folds were reduced at the neuromuscular 
junctions in utrophin-deficient skeletal muscle. Despite 
these subtle derangements, the overall structure of the 
mutant synapse was qualitatively normal, and the spe-
cialized characteristics of the dystrophin-associated 
protein complex were preserved at the mutant neuro-
muscular junction. These results point to a predomi-
nant role for other molecules in the differentiation and 
maintenance of the postsynaptic membrane.
 
U
 
trophin
 
 and dystrophin are large (
 
.
 
400 kD), ho-
mologous, membrane-associated cytoskeletal pro-
teins (Blake et al., 1996
 
a
 
; Ahn and Kunkel, 1993).
In skeletal muscle, dystrophin binds to a large multimolec-
ular complex (the dystrophin-associated protein complex
or DPC)
 
1
 
 that spans the plasma membrane and links the
cytoskeleton to the extracellular matrix (Ervasti and Camp-
bell, 1993; Matsumura and Campbell, 1994). Disruption of
the dystrophin gene leads to Duchenne or Becker muscu-
lar dystrophy (Hoffman et al., 1987). Genes encoding sev-
eral components of the DPC are now known to be mu-
tated in other congenital muscular dystrophies (Campbell,
1995). Together, these results suggest that dystrophin and
the DPC provide crucial structural support to the contract-
ing muscle fiber.
Utrophin was isolated by virtue of its similarity to dys-
trophin (Love et al., 1989; Khurana et al., 1990). Sequenc-
ing revealed the two proteins to be homologous along
their entire length (Tinsley et al., 1992). Moreover, like
dystrophin, utrophin is transcribed from multiple promot-
ers (Pearce et al., 1993; Blake et al., 1995) and appears to
associate with the DPC (Matsumura et al., 1992). Utro-
phin is expressed in a variety of muscle and nonmuscle tis-
sues in both embryos and adults (Love et al., 1991; Clerk
et al., 1993; Koga, 1993; Schofield et al., 1993; Mora et al.,
1996; Ohlendieck et al., 1991; thiMan et al., 1991; Khurana
et al., 1991). Despite a growing body of knowledge about
the distribution and regulation of utrophin its functions re-
main unknown.
Interest in utrophin has largely centered on three issues.
First, in adult skeletal muscle dystrophin is present through-
out the sarcolemma whereas utrophin is exclusively associ-
ated with the neuromuscular junction (NMJ) (Ohlendieck
et al., 1991; thiMan et al., 1991; Khurana et al., 1991; Byers
et al., 1991; Sealock et al., 1991; Bewick et al., 1992). This
selective localization, along with additional experiments
on the expression and effects of utrophin in cultured cells
(see Discussion), suggested the hypothesis that utrophin
plays a role in synaptogenesis. Moreover, 
 
a
 
-dystroglycan,
a membrane component of the DPC, binds tightly to agrin,
a neurally derived promoter of acetylcholine receptor
(AChR) clustering (Campanelli et al., 1994; Gee et al.,
1994; Sugiyama et al., 1994; Bowe et al., 1994). Together,
these results led to the specific proposal that utrophin
might be involved in the formation and/or maintenance of
the high density aggregates of AChR with which it pre-
cisely codistributes in the postsynaptic membrane (Byers
et al., 1991; Sealock et al., 1991; Bewick et al., 1992). Sec-
ond, utrophin is present is several tissues, such as lung and
kidney, in which dystrophin is undetectable (Love et al.,
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1991; Khurana et al., 1991; Schofield et al., 1993). This dif-
ferential distribution together with the fact that some com-
ponents of the DPC exist in these tissues (Ervasti and
Campbell,  1993; Durbeej et al., 1995), suggests that utrophin
could substitute for dystrophin to form a homologous mem-
brane-spanning complex required for cellular integrity. In-
deed, the absence of known spontaneous mutations in the
utrophin gene, despite its enormous size (
 
z
 
1.0 Mb; Pearce
et al., 1993), has raised the possibility that its disruption
might be embryonically lethal (Blake et al., 1996
 
a
 
). Third,
levels of utrophin are increased in muscles of dystrophin-
deficient humans and mice (Khurana et al., 1991; Mat-
sumura et al., 1992; Pons et al., 1994
 
b
 
). It has been sug-
gested that this upregulation serves as a compensatory
mechanism; and in fact, the muscles which have the great-
est upregulation of utrophin show the least pathological
changes in dystrophin-deficient (mdx) mice (Matsumura et
al., 1992). If utrophin can compensate functionally for dys-
trophin, it might be possible to treat patients with Du-
chenne muscular dystrophy by increasing expression of
their normal utrophin gene (Blake et al., 1996
 
a
 
; Ahn and
Kundel, 1993; Matsumura and Campbell, 1994).
As a first step toward testing these hypotheses, we have
generated and characterized utrophin-deficient mice. Sur-
prisingly, the mutants were viable and fertile, and dis-
played no severe abnormalities in muscle and nonmuscle
tissues. Detailed analysis of the NMJ showed, however,
that utrophin is required for complete differentiation of
the postsynaptic membrane.
 
Materials and Methods
 
Generation of Mutant Mice
 
To construct a targeting vector we isolated a 14-kb genomic fragment
from a 129 mouse genomic library (Stratagene, La Jolla, CA). The frag-
ment contained a single 75-bp exon that encoded amino acids 2851-2875
of the mouse utrophin protein and corresponded to exon 64 of the dystro-
phin gene (Fig. 1 
 
a
 
). The long arm of homology in the targeting vector was
a 9.5-kb SphI genomic fragment directly upstream of the isolated exon.
The short arm was a 1.1-kb BstBI–BamHI fragment that included the dis-
tal 25-bp of the exon. These fragments were inserted into cloning sites
flanking a PGKneomycin resistance cassette (Tybulewicz et al., 1991). The
vector included a thymidine kinase cassette distal to the short arm. The
mutant gene therefore lacked the 
 
z
 
2.7-kb SphI–BstBI fragment which in-
cluded the first 52 bp of the isolated exon. The vector was linearized with
NotI and transferred into R1 type embryonic stem (ES) cells (Nagy et al.,
1993) by electroporation. Homologous recombinants were isolated by
double selection using G418 and FIAU. Chimeras from two indepen-
dently derived ES cells gave rise to heterozygous and homozygous mu-
tants. The phenotypes of the two lines were indistinguishable and the re-
sults obtained with both lines are presented together.
 
Molecular Analysis
 
For Southern analysis, DNA from adult liver was digested with NheI and
NcoI and probed with a 
 
32
 
P-labeled BstBI–BamHI fragment of the utro-
phin genomic clone (Fig. 1 
 
b
 
).
For reverse transcription-polymerase chain reaction (RT-PCR) analy-
sis, total RNA was isolated from adult tissues and cDNA was made using
AMV-RT (Promega, Madison, WI) and random primers. Four oligonu-
cleotides, which flanked the mutated exon by 597, 197, 214, and 554 bp
(primers b, a, a
 
9
 
, and b
 
9
 
, respectively, in Fig. 1 
 
c
 
), were used pairwise to
amplify reverse transcribed RNA from 
 
utrn
 
1
 
/
 
2
 
 and 
 
utrn
 
1
 
/
 
2
 
 muscle. The
resulting fragments were then sequenced.
For immunoblots, tissue was homogenized and sonicated in extraction
buffer (phosphate-buffered saline [PBS], 1% SDS, 5 mM EDTA, and pro-
tease inhibitors). Aliquots of a low speed supernatant were analyzed for
 
total protein concentration using a BCA protein assay (Pierce, Rockford, IL);
30 
 
m
 
g of total protein was loaded per lane on 6% SDS polyacrylamide gels.
 
Histological Analysis
 
For immunohistochemical analysis, tissue was frozen in liquid nitrogen-
cooled isopentane and sectioned at 7 
 
m
 
m. Sections were stained with anti-
bodies diluted in PBS with 1% BSA for 2–12 h, then rinsed with PBS.
Sections were then incubated with a mixture of contrasting flurophores:
fluorescein-conjugated goat anti–mouse IgG1 or goat anti–rabbit IgG and
rhodamine-conjugated 
 
a
 
-bungarotoxin (BTX) or goat anti–rabbit IgG.
For thick sections, the sternomastoid was fixed in 1% paraformaldehyde
in PBS, cryoprotected in sucrose, frozen, and sectioned en face at 40 
 
m
 
m.
Sources of antibodies were as follows: mouse monoclonal antibodies to
utrophin, dystrophin, 
 
b
 
-dystroglycan, and 
 
a
 
-sarcoglycan (adhalin) were pur-
chased from Novocastra Laboratories Ltd. (Newcastle upon Tyne). A rab-
bit polyclonal anti-utrophin antibody was made in our laboratory to a
peptide corresponding to the final 10 COOH-terminal amino acids from
murine utrophin. A rabbit antiserum to dystrobrevin was made to a fusion
protein containing a 292–amino-acid fragment from murine dystrobrevin.
Sources for antibodies to agrin, laminin-
 
b
 
2, laminin-1, synaptophysin, and
rapsyn are described in previous publications from our laboratory (Sanes
et al., 1990; Gautam et al., 1995; Gautam et al., 1996). Antibodies to MuSK
(DeChiara et al., 1996) and 
 
b
 
2-syntrophin (Peters et al., 1994) were gener-
ous gifts of G. Yancopoulos (Regeneron) and S. Froehner (University of
North Carolina), respectively.
For ultrastructural studies, sternomastoid and intercostal muscles were
fixed in 4% glutaraldehyde/4% paraformaldehyde in PBS, washed, re-
fixed in 1% OsO4, dehydrated, and embedded in resin. Thin sections were
stained with lead citrate and uranyl acetate. Sections were systematically
scanned in the electron microscope, and all NMJs encountered were pho-
tographed at 20,000
 
3
 
. Lengths of nerve-muscle apposition were measured
from the micrographs, and junctional folds that opened into the primary
cleft were counted and expressed as folds per micron of apposition. Re-
sults did not differ significantly between sternomastoid and intercostals, so
data have been pooled.
 
Quantitation of AChR
 
AChR density was assessed by fluorescence imaging, a method devised
and described by Turney et al. (1996). Briefly, live mice were anesthetized
and the sternomastoid was incubated with a saturating dose of rhodamine-
BTX for 30 min. The neuromuscular junctions were visualized using a flu-
orescence microscope and a video camera. Quantitative images were ob-
tained by storing the ratio of junctional fluorescence to that of a fluorescent
standard. These images were stored in a digital image processor. For anal-
ysis, 2–4 intensity profiles were taken from separate parts of each neuro-
muscular junction. Dedicated computer software then gave each profile a
single value representing its relative illumination intensity. Two 
 
utrn
 
1
 
/
 
2
 
(70 intensity profiles from 24 endplates) and two 
 
utrn
 
2
 
/
 
2
 
 mice (67 inten-
sity profiles from 21 endplates) were studied.
For AChR quantitation by 
 
125
 
I-BTX, the sternomastoid was dissected
and placed in oxygenated buffer containing 50 nm 
 
125
 
I-BTX (Amersham).
Muscles were incubated for 2 h, washed extensively, and fixed with 4%
paraformaldehyde/5% sucrose in PBS. The muscles were then teased into
small muscle bundles, endplates were visualized with an anticholines-
terase stain, and counted. The small bundles were then divided into two
equal sections, one with and one without endplates, and counted in a
gamma counter. Specific counts were the difference between the two.
 
Results
 
Generation of utrn
 
2
 
/
 
2
 
 Mice
 
Utrophin, like dystrophin, is comprised of four structural
domains (Fig. 1 
 
a
 
; Tinsley et al., 1992; Blake et al., 1996):
an amino-terminal segment that contains a putative actin-
binding site, a long central rod, a highly conserved cys-
teine-rich region, and a COOH-terminal domain with ho-
mology to only two other known proteins, dystrobrevin
(Wagner et al., 1993; Blake et al., 1996
 
a
 
) and DRP2 (Rob-
erts et al., 1996). In addition, both utrophin and dystrophin
exist in shorter forms, reflecting both alternative splicing 
Grady et al. 
 
Utrophin Mutant Mice
 
873
 
and transcription from multiple promoters (Pearce et al.,
1993; Ahn and Kunkel, 1993; Blake et al., 1995, 1996
 
a
 
).
These shorter forms lack some or all of the NH
 
2
 
-terminal,
central rod, and COOH-terminal domains, but all known
forms share the cysteine-rich region (Ahn and Kunkel,
1993; Blake et al., 1996
 
a
 
). This region is required for bind-
ing of dystrophin and, by implication, of utrophin to the
DPC (Suzuki et al., 1994; Rafael et al., 1996); furthermore,
deletion of this part of dystrophin leads to a severe dystro-
phic phenotype (Bies et al., 1992). To maximize our chance
of disrupting the function of all known utrophin isoforms,
we targeted an exon that maps to the beginning of utro-
phin’s cysteine-rich region (Fig. 1 
 
a
 
). The mutation was
transferred by homologous recombination to embryonic
stem (ES) cells, which were then used to generate germ-
line chimeras. Heterozygous (
 
utrn
 
1
 
/
 
2
 
) mice appeared
normal and homozygous (
 
utrn
 
2
 
/
 
2
 
) mice were produced
in expected numbers. Southern analysis confirmed disrup-
tion of the utrophin gene (Fig. 1 
 
b
 
).
The effects of the mutation on utrophin RNA were as-
sessed by reverse transcription PCR (RT-PCR) (Fig. 1 
 
c
 
).
We used primers that flanked the targeted 75-bp exon (cor-
responding to exon 64 of the dystrophin gene) by 197 and
214 bp. Reverse transcripted RNA from wild-type and
mutant muscle was amplified by PCR using these primers.
The expected 486-bp fragment was amplified from wild-type
muscle, whereas a smaller (349 bp) fragment was ampli-
fied from mutant muscle. Sequencing of the PCR products
revealed the mutant transcript to contain a 137-bp dele-
tion encompassing not only the targeted exon but the pre-
ceding exon as well (corresponding to exon 63 of the dys-
trophin gene). These exons are located at the start of the
cystein-rich region (Fig. 1 
 
c
 
). This deletion leads to a frame-
shift that introduces a stop codon 1.7-kb before the wild-
type stop codon and theoretically results in a truncated
utrophin protein missing both the cysteine-rich and the
COOH-terminal domains. To seek transcripts with larger
deletions, we repeated this analysis with primers that
Figure 1. Generation of utrophin deficient mice. (a) Structure of the utrophin protein (line 1), a genomic fragment (line 2), the targeting
vector (line 3), and the predicted product of homologous recombination (line 4). In line 1, A 5 actin-binding domain, R 5 rod domain,
and C 5 cysteine-rich domain (hatched area). The solid box in line 2 represents the targeted exon that encodes the beginning of the cys-
teine-rich region. The probe used for Southern analysis is indicated in line 4. S, SphI; Bst, BstBI; B, BamHI; Nhe, NheI; Nco, NcoI. (b)
Southern blot analysis of NcoI–NheI digested genomic DNA. The 4.2-kb fragment of the wild-type allele was altered to a 2.3-kb frag-
ment in the mutant. (c) RT-PCR analysis of total RNA. Panel 1 shows the PCR results using primers a and a9. A 486-bp wild-type PCR
fragment was altered to a 349-bp fragment in the mutant transcript. Sequencing of the PCR product revealed that the 137-bp deletion
corresponded to bp 8624-8787 of the utrophin cDNA. Full-length utrophin cDNA was used as the template in lane 1 (wt). Panel 2 shows
the location of the PCR primers in relation to utrophin’s cysteine-rich domain (hatched box). The smaller bar indicates the region of
utrophin protein encoded by the targeted exon, amino acids 2850-2875. The larger bar spans the region of utrophin deleted in the mu-
tant RNA, corresponding to amino acids 2829-2875. This mutation results in a stop codon (*) at amino acid 2884. Both sets of flanking
primers (a, a9 and b, b9) detected the same deletion. (d) Immunoblots of protein extracts from muscles and lungs of utrn1/2 and utrn2/2
animals using antibodies to the NH2 (N-UTR) and COOH-terminal (C-UTR) portion of utrophin and the COOH-terminal portion of
dystrophin (DYST). Both utrophin and dystrophin migrate at z400 kD. 
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flanked the targeted exon by 597 and 554 bp. Only the 137-
bp-deleted product was recovered, suggesting that, at least
in skeletal muscle, the mutated utrophin gene gives rise
only to mRNAs that encode truncated proteins lacking the
cysteine-rich and COOH-terminal domains.
Consistent with the RT-PCR analysis, immunoblotting
with an antibody specific to the COOH terminus of utro-
phin failed to react with any protein in 
 
utrn
 
2
 
/
 
2
 
 skeletal
muscle (Fig. 1 
 
d
 
). However, an NH
 
2
 
-terminal specific anti-
body also failed to detect protein, indicating that truncated
utrophin is either not produced or is unstable. Similar re-
sults were obtained in adult brain and lung and in neonatal
muscle (Fig. 1 
 
d
 
 and data not shown). Thus, the 
 
utrn
 
2
 
/
 
2
 
mutant we have generated is likely a severe hypomorph
for all forms of utrophin.
 
Immunohistochemical Analysis of utrn
 
1
 
/
 
2
 
and utrn
 
2
 
/
 
2
 
 Tissue
 
Despite the absence of utrophin, 
 
utrn
 
2
 
/
 
2
 
 mice developed
normally, were fertile and have now lived for 10 mo with-
out any obvious pathology. To evaluate sublethal conse-
quences of utrophin-deficiency, we examined several tis-
sues that normally express utrophin: brain, heart, lung,
kidney, and skeletal muscle (Love et al., 1989). We first as-
sessed the cellular distribution of utrophin in normal adult
tissue. In the brain, utrophin was present in the microvas-
culature (Fig. 2 
 
a
 
), the choroid plexus and the pia mater, as
previously noted by others (Khurana et al., 1992; Uchino
et al., 1994). This pattern suggests that utrophin may be a
part of the blood-brain barrier. In cardiac muscle, we
Figure 2. Immunohistochemical analysis of brain, heart, lung, and kidney from adult utrn1/2 and utrn2/2 mice. Tissues were doubly
stained with a mixture of fluorescein-tagged antibodies to the NH2- and COOH-termini of utrophin (a–h) plus a rhodamine-tagged anti-
body to laminin-1 (a9–h9). Each pair of micrographs presents two views of a single field photographed with filters selective for each fluo-
rophore. (a and b) A small cerebral vessel; (c and d) a longitudinal section through cardiac myocytes; (e and f) alveoli in lung; and (g and
h) a renal glomerulus. In utrn1/2 mice, utrophin-rich cells abut laminin-rich basal laminae (a9, c9, e9, and g9). In mutants, utrophin is un-
detectable, but laminin staining shows that normal tissue architecture is preserved (b9, d9, f9, and h9). Bar in h9 is 50 mm.Grady et al. Utrophin Mutant Mice 875
Figure 3. Immunohistochemical analysis of skeletal muscle from adult utrn1/2 and utrn2/2 mice. Sections of adult skeletal muscle
were double stained with a fluorescein-tagged antibody to the protein listed in each row (a–n), plus with a rhodamine-BTX to label
AChR (a9–n9). In a–d, N and C denote antibodies to the NH2- and COOH-termini of utrophin, respectively. Each pair of micrographs
presents two views of a single field photographed with filters selective for each fluorophore. Utrophin staining was absent in utrn2/2
muscle (b and d). The distribution of other proteins was similar in utrn1/2 and utrn2/2 muscle. Bar in n9 is 20 mm.The Journal of Cell Biology, Volume 136, 1997 876
found utrophin associated with both intercalated discs and
sarcolemma (Fig. 2 c); in contrast, a previous report found
utrophin only at intercalated discs (Pons et al., 1994a). In
lung, utrophin localized to the membrane of most if not all
the cells of the alveoli (Fig. 2 e) but was not detectable in
bronchiolar or pulmonary arterial endothelium. In kidney,
utrophin was localized to the cells adjacent to the glomer-
ular basement membrane and to the basolateral mem-
brane of a subset of tubules (Fig. 2 g). In skeletal muscle,
utrophin was confined to the NMJ (Fig. 3, a and c), as de-
tailed below.
In all tissues studied, utrophin-rich membranes abutted
basal laminae, as revealed by counterstaining with anti-
bodies to the ubiquitous basal lamina component, laminin
(Fig. 2, a9, c9, e9, and g9 and data not shown). Based on this
association, we used laminin counterstaining to seek resid-
ual utrophin expression in utrn2/2 mice and to look for
any histological abnormalities in cells that normally ex-
press utrophin. No utrophin immunoreactivity was detect-
able in any of the utrn2/2 tissues studied (Fig. 2, b, d, f,
and h, and 3, b and d). Moreover, the arrangement of basal
laminae and, by implication, of the cells that abut them,
were normal in all utrn2/2 tissue (Fig. 2, b9, d9, f9, and h9
and data not shown). In support of this conclusion, no
structural abnormalities were detected in hematoxylin-
eosin stained sections (data not shown). Similarly, utro-
phin was undetectable and the tissues histologically nor-
mal in heart, brain, lung, and skeletal muscles from neona-
tal (P1) utrn2/2 mice (data not shown).
Limited investigations have failed so far to reveal any
significant functional consequences of utrophin-deficiency:
(1) Serial observations detected no behavioral, motor or
cardiorespiratory defects. (2) Urinalysis showed no signifi-
cant proteinuria in the mutant animals. (3) Mutant mice had
no evidence of a disrupted blood-brain barrier as shown
by the exclusion of Evans Blue from the brain parenchyma
Figure 4. Structure and AChR density of the NMJ in utrn1/2 and utrn2/2 mice. (a and b) Longitudinal sections of adult muscle
stained with rhodamine-BTX. Size and geometry of utrn2/2 endplates were similar to those in utrn1/2 muscle. (c) Histogram depict-
ing the illumination intensity for each observation made from synapses of utrn1/2 and utrn2/2 mice. Arrows depict average illumina-
tion intensity 6 SEM for each genotype. Utrn2/2 synapses have z30% fewer AChR than utrn1/2 synapses. Bar in b is 10 mm for a
and b.Grady et al. Utrophin Mutant Mice 877
(Chiueh et al., 1978). (4) Utrophin-deficient mothers bore
normal-sized litters and reared their offspring appropri-
ately. (5) Mutant neonates remained viable and active
even when separated from their mothers for >4 h.
Decreased AChR Density and Junctional Folds at the 
utrn2/2 Synapse
Given the selective association of utrophin with the NMJ
(Fig 3, a and c) and its putative role in synaptogenesis (see
Discussion), we suspected that subtle defects might be
present and therefore analyzed the NMJ in detail. Label-
ing the AChR with rhodamine-BTX (Fig. 4, a and b) and
the nerve terminals with antibodies to synaptic vesicle pro-
teins (not shown) revealed the utrn2/2 synapse to be of
normal size and geometry (Fig. 4, a and b). However, the
density of AChR was z30% lower in utrn2/2 than in
utrn1/2 muscle as assessed by fluorescence-imaging fol-
lowing  incubation with rhodamine-BTX (Turney et al.,
1996) (utrn2/2: 39.5 6 0.9, n 5 67; utrn1/2: 55.5 6 1.6, n
5 70; illumination intensity 6 standard error of the mean,
n 5 number of synaptic images analyzed; P , .0001 by
Mann-Whitney). This difference appeared to reflect a
moderate decrease in AChR density at most synapses
rather than a drastic decrease in density at a specific subset
of synapses (Fig. 4 c). Preliminary measurements of a total
number of AChR using 125I-BTX gave results suggesting a
similar reduction (data not shown). The outwardly normal
motor behavior of the utrn2/2 mice despite the signifi-
cant decrease in AChR is consistent with the known safety
margin in the number of AChR required for normal mus-
cle function (Patton and Waud, 1967).
Further abnormalities were discovered when muscles
were analyzed by electron microscopy. In normal muscle,
junctional folds invaginate the postsynaptic membrane;
AChR and utrophin are concentrated at the tops of these
folds (Sealock et al., 1991; Bewick et al., 1992). In utrn2/2
sternomastoid and intercostal muscles, the number of
folds was reduced by z50% compared to utrn1/2 and
utrn1/1 synapses (Fig. 5). This difference was apparent
by P11 and persisted into adulthood. Despite the decrease
in junctional folds, the mutant synapse displayed normal
apposition of Schwann cell to nerve and of nerve to muscle
as well as normally differentiated nerve terminals (Fig. 5,
a–d). Thus, although utrophin is clearly not essential for
neuromuscular synaptogenesis, the utrn2/2 mice show
morphological as well as molecular alterations in their
postsynaptic apparatus.
The Dystrophin-associated Protein Complex at
utrn2/2 Synapses
In skeletal muscle, dystrophin and the dystrophin-associ-
ated protein (DPC) join the actin cytoskeleton to the ex-
tracellular matrix protein laminin-2 providing structural
support to the sarcolemma (Ervasti and Campbell, 1993;
Matsumura and Campbell, 1994). The DPC is found at the
synapse as well, but in an altered form. Intracellularly, dys-
trophin and a1-syntrophin are present throughout the sar-
colemma, whereas utrophin and b2-syntrophin are exclu-
sively synaptic (Ohlendieck et al., 1991; thiMan et al., 1991;
Khurana et al., 1991; Peters et al., 1994). Extracellularly,
the b1 chain of the laminin heterotrimer is replaced by
laminin-b2 in synaptic basal lamina (Sanes et al., 1990). In
addition, agrin, a protein responsible for AChR clustering
(Gautam et al., 1996), is concentrated in the synaptic cleft
and binds to the extracellular portion of the DPC (Cam-
panelli et al., 1994; Gee et al., 1994; Sugiyama et al., 1994;
Bowe et al., 1994). Finally, studies with recombinant pro-
teins have suggested that the synaptic DPC associates with
the AChR-associated protein, rapsyn (Apel et al., 1995),
which in turn associates with MuSK (Gillespie et al., 1996),
a tyrosine kinase receptor thought to mediate the effects
of agrin (DeChiara et al., 1996).
The utrophin-deficient mice allowed us to ask whether
utrophin is needed for the DPC to acquire its specialized
synaptic characteristics. We immunostained for the syn-
apse-specific proteins rapsyn, b2-syntrophin, laminin b2,
agrin, and MuSK. All of these antigens were concentrated
at synaptic sites in both utrn1/2 and utrn2/2 mice (Fig. 3,
k–n, and data not shown). In addition, we assayed the
more broadly distributed DPC proteins b-dystroglycan,
dystrobrevin, a-sarcoglycan, and dystrophin. These pro-
teins were also normally distributed in utrn2/2 skeletal
muscle (Fig. 3, e–j, and data not shown). Thus, the synaptic
DPC can exist and maintain its specialized character in the
absence of utrophin.
One possible explanation for the maintenance of post-
synaptic specialization in the utrn2/2 mouse is that a syn-
aptic concentration of dystrophin substitutes for utrophin.
Indeed, utrophin and dystrophin are both concentrated at
the adult synapse (Fig. 3, a, c, and e), although their pre-
cise distribution differs: utrophin colocalizes with AChRs
at the crests of the junctional folds whereas dystrophin is
primarily at the base of the folds (Byers et al., 1991; Sea-
lock et al., 1991; Bewick et al., 1992). In newborn (P1) ani-
mals, utrophin was already enriched at the endplate, al-
though some extrasynaptic staining was evident as well
(Fig. 6 a). Dystrophin, on the other hand, was not yet en-
riched at the endplate at birth (Fig. 6 c), presumably re-
flecting the postnatal formation of junctional folds which
continues for several weeks after birth. If dystrophin com-
pensated for utrophin, then one might expect dystrophin
to become enriched at the neonatal mutant synapse. In
utrn2/2 neonates, however, dystrophin remained evenly
distributed throughout the sarcolemma with no synaptic
enrichment (Fig. 6 d). Nonetheless, rapsyn and AChR re-
mained concentrated at the neonatal utrn2/2 synapse
(Fig. 6, e, e9, f, and f9). Thus, the localization of the AChR-
rapsyn complex to the postsynaptic membrane can occur
when neither utrophin nor dystrophin is synaptically con-
centrated.
Dystrophin and the DPC in Tissues Other than 
Skeletal Muscle
Functional compensation by dystrophin may help explain
the normal structure of tissues other than skeletal muscle
in utrn2/2 mice. We examined this hypothesis by assess-
ing the distribution of dystrophin in several tissues that
normally express utrophin. In normal heart and brain, dys-
trophin and utrophin had overlapping distributions; both
were localized to the sarcolemma and intercalated discs in
cardiac myocytes and to endothelial cells in the cerebral
vasculature (Fig. 2 c, 7, a and c and data not shown). TheThe Journal of Cell Biology, Volume 136, 1997 878
distribution of dystrophin in heart and brain of utrn2/2
mutants did not differ detectably from that in controls
(Fig. 7 d, and data not shown). Moreover, the DPC com-
ponent b-dystroglycan was distributed along the sarco-
lemma at similar levels in utrn1/2 and utrn2/2 cardiac
myocytes (Fig. 7, e and f). Thus, in these tissues, dystro-
phin is appropriately placed to compensate for the loss of
utrophin.
In contrast, we detected no dystrophin in lung or kidney
of either utrn1/2 or utrn2/2 mice (Fig. 7, i and j, and data
not shown). The antibody we used was specific for the
COOH terminus of dystrophin, and therefore should have
detected short forms as well as full-length dystrophin. Low
levels of dystrophin have been detected in these tissues by
immunoblot analysis (e.g., Hoffman et al., 1988); these lev-
els may have been too low to be detected by our immuno-
histochemical assay. Nonetheless, compensation by upregu-
lation of dystrophin is unlikely in these tissues. In light of
this result, we used the lung to determine whether compo-
nents of the DPC persist in the apparent absence of both
utrophin and dystrophin. In dystrophic muscle, loss of dys-
trophin leads to a marked decrease in the levels of DPC
Figure 5. Ultrastructure of
the NMJ in utrn1/2 and
utrn1/2 mice. (a–d) Electron
micrographs of NMJs from
P11 (a and b) and P50 mice (c
and  d). Nerve terminals and
Schwann cells appeared nor-
mal in the mutant, but there
were fewer junctional folds in
mutant than in control postsyn-
aptic membranes. (e) Average
number of folds per micron
of primary synaptic cleft in
utrn1/1,  utrn1/2, and utrn2/2
mice at P11 and P50. Each bar
shows mean 6 SEM of mea-
surements from 37–136 syn-
apses. Bar in d is 1 mm for a–d.Grady et al. Utrophin Mutant Mice 879
components in the sarcolemma (Matsumura et al., 1992). In
lung, however, one component of the DPC, b-dystroglycan,
was present in similar levels in utrn1/2 and utrn2/2 mice
(Fig. 7, k and l). This result implies the existence of a utro-
phin- and dystrophin-independent mechanism for retention
of the DPC.
Discussion
Mice lacking a functional utrophin gene are viable and fer-
tile, but have subtle defects in the postsynaptic apparatus
of their skeletal neuromuscular junctions. In an accompa-
nying paper, Deconinck et al. (1997) reported similar re-
sults. The allele described here removes the COOH-termi-
nal cysteine-rich region that is shared by both forms of
utrophin (Blake et al., 1995), and is likely, by analogy to
dystrophin, to be important for its function (Bies et al.,
1992; Suzuki et al., 1994; Rafael et al., 1996). In fact, no
utrophin at all was detectable in our mutant, either be-
cause insertion of the neomycin cassette led to reduced
levels of mRNA or because the mutant protein was unsta-
ble. We cannot rule out, however, the possibility that trun-
cated utrophin is present in some tissues or at some stages
of development. Deconinck et al. (1997) deleted an NH2-
terminal exon, leading to complete loss of full-length utro-
phin. They, however, cannot exclude the possibility that
shorter forms of utrophin, transcribed from a promoter
COOH-terminal to their deletion (Blake et al., 1995), are
present in the mutant. Thus, the similarity of the pheno-
type reported here to that reported by Deconinck et al.
(1977) provides a strong argument that both alleles are ef-
fectively nulls.
Utrophin and Synaptogenesis
Four sets of studies had suggested that utrophin might be
critical for neuromuscular synaptogenesis and particularly
for the differentiation of the postsynaptic membrane. First,
agrin, a critical organizer of postsynaptic differentiation
(Gautam et al., 1996), binds to dystroglycan, a component
of the DPC (Campanelli et al., 1994; Gee et al., 1994; Su-
giyama et al., 1994; Bowe et al., 1994). Dystroglycan, in turn,
appears to associate with utrophin at the NMJ and with
dystrophin extrasynaptically (Matsumura et al., 1992; Er-
vasti and Campbell, 1993). It seemed possible, therefore,
that utrophin converted synaptic dystroglycan into a func-
tional agrin receptor. Second, in cultured muscle cells, large
but not small AChR clusters are associated with utrophin,
suggesting that utrophin is important for the growth or sta-
bilization of high density AChR aggregates (Phillips et al.,
1993; Campanelli et al., 1994). Third, mice incapable of
forming postsynaptic AChR clusters through targeted mu-
tagenesis of rapsyn (Gautam et al., 1995), MuSK (DeChi-
ara et al., 1996), or agrin (Gautam et al., 1996), lack synap-
tic accumulations of utrophin. Finally, forced expression
of the putative dystroglycan binding domain of utrophin in
cultured myotubes leads to fewer AChR clusters in re-
sponse to agrin (Namba and Scheller, 1997). This pre-
sumptive dominant negative effect suggested that interfer-
ing with the utrophin-dystroglycan association attenuates
the agrin-mediated AChR cluster transduction pathway.
The modest reduction in AChR density that we and De-
coninck et al. (1977) find in the utrn2/2 mice provides
limited support for the involvement of utrophin and the
DPC in postsynaptic differentiation. The nature of this in-
volvement, however, remains unclear. One possibility is
Figure 6. Immunohistochemcial analysis of neonatal skeletal muscle from utrn1/2 and utrn2/2 mice. (a and b) Muscle stained with an
NH2-terminal utrophin antibody. Utrophin is concentrated at synaptic sites in utrn1/2 muscle by P1, but low levels are also present ex-
trasynaptically. (c and d) Muscle stained for dystrophin shows no synaptic enrichment in either utrn1/2 or utrn2/2 muscle. (e and f)
Rapsyn maintains its synaptic localization in utrn2/2 muscle. (a9–f9) AChR labeled with rhodamine-BTX. Bar in d is 20 mm.The Journal of Cell Biology, Volume 136, 1997 880
that utrophin-DPC dependent processes are required for
complete AChR clustering but that other pathways play a
dominant role in transmitting agrin’s signals. For example,
there is now evidence that a synaptically localized tyrosine
kinase, MuSK, is part of or associated with a functional
agrin receptor (DeChiara et al., 1996; Glass et al., 1996).
Moreover, agrin fragments that are incapable of binding
dystroglycan retain their AChR clustering activity in vitro
(Sugiyama et al., 1994; Gesemann et al., 1995, 1996; Cam-
panelli et al., 1996).
A second possibility is that utrophin and the synaptic
DPC might actually be crucial for postsynaptic differentia-
tion, but that dystrophin substitutes, albeit imperfectly, for
utrophin in the utrn2/2 mice. In this context, it is note-
worthy that mutation of the dystroglycan gene leads to a
far more severe phenotype than mutation of either the
utrophin or the dystrophin gene (cited in Henry and
Campbell, 1996). Moreover, a reduction in the density of
junctional folds is also seen at NMJs of dystrophin-defi-
cient (mdx) mice. In this case, however, the synaptic alter-
ations are thought to result from muscle fiber necrosis and
regeneration, rather than from the absence of dystrophin
per se (Torres and Duchen, 1987; Lyons and Slater, 1991).
A third possibility is that the decreased density of
AChRs in utrn2/2 mice may result from the decreased
number of junctional folds. In normal skeletal muscle,
AChRs are concentrated not only at the tops of folds but
also partway down their sides (Fertuck and Salpeter,
1976). A loss of folds would, therefore, lead to a decrease
in the total AChR-rich area within the NMJ. In this sce-
nario, the decreased AChR density in utrn2/2 muscle
would not result from any functionally important interac-
tion of utrophin or the DPC with AChRs. Instead, the di-
rect effect of utrophin in muscle might be to promote the
initial invagination of the postsynaptic membrane that
leads to the generation of folds.
Utrophin in Nonskeletal Tissues
In contrast to the neuromuscular phenotype, we detected
no abnormalities in other tissues that express utrophin.
The early and widespread expression of utrophin led to
the speculation that utrophin-deficiency might lead to em-
bryonic lethality (Blake et al., 1996a). This hypothesis,
which we have now disproven, provided an attractive ex-
planation for the fact that no mutations of the human utro-
phin gene have yet been reported despite its extremely
large size (Pearce et al., 1993). It is premature, however, to
conclude that utrophin is unimportant for the function of
nonskeletal tissues. In fact, the histological analysis so far
applied to nonskeletal tissue also failed to detect defects in
muscle. A more detailed analysis will be required to deter-
mine whether utrophin plays a role in such structures as
the glomerular filter or the blood-brain barrier.
Figure 7. Immunohistochemical analysis of neonatal heart (a–f) and lung (g–l) from utrn1/2 and utrn2/2mice. Utrophin is widely dis-
tributed in control heart and lung (a and g), but is undetectable in utrn2/2 heart and lung (b and h). Dystrophin was associated with the
sarcolemma in both utrn1/2 and utrn2/2 hearts (c and d), but was absent from both utrn1/2 and utrn2/2 lung (i and j). b-Dystroglycan
was associated with the membrane of cardiac myocytes (e and f) and aveoli (k and l) in both utrn1/2 and utrn2/2 mice.Grady et al. Utrophin Mutant Mice 881
Functional Redundancy
Utrophin levels are increased in dystrophin-deficient ani-
mals, suggesting that it may functionally compensate, in
part, for the missing dystrophin (Ahn and Kunkel, 1993;
Matsumura and Campbell, 1994; Blake et al., 1996a). We
asked whether the reverse was true in utrn2/2 mice. We
obtained, however, no evidence that dystrophin was up-
regulated in utrophin-deficient tissue. Indeed, lung and
kidney appeared histologically and functionally normal in
the absence of detectable utrophin or dystrophin. More-
over, the NMJ can maintain its specialized character even
when neither utrophin nor dystrophin is concentrated at
synaptic sites. We still cannot exclude the possibility that
an undetected isoform of dystrophin, or a dystrophin ho-
mologue such as dystrobrevin (Wagner et al., 1993; Blake
et al., 1996b) or DRP2 (Roberts et al., 1996), might be com-
pensating for the loss of utrophin. Fortunately, it will be
possible to test this hypothesis since dystrophin-deficient
(mdx) mice are available, and we have now generated dys-
trobrevin-deficient mice which are viable and fertile (Grady,
R.M., Merlie, J.P., and Sanes, J.R., manuscript in prepara-
tion). We are now breeding these animals to generate dou-
bly mutant mice deficient in utrophin and either dystro-
phin or dystrobrevin.
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